Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Gains from Sales and Divestitures (2023 - 2025)

Ocular Therapeutix (OCUL) has 4 years of Gains from Sales and Divestitures data on record, last reported at $1.6 million in Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 21.47% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, up 21.47%, while the annual FY2025 figure was $1.6 million, 21.47% up from the prior year.
  • Gains from Sales and Divestitures reached $1.6 million in Q4 2025 per OCUL's latest filing, up from $1.3 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.6 million in Q4 2025 and bottomed at $393805.0 in Q4 2023.
  • Average Gains from Sales and Divestitures over 3 years is $1.1 million, with a median of $1.3 million recorded in 2024.
  • Peak YoY movement for Gains from Sales and Divestitures: soared 224.37% in 2024, then rose 21.47% in 2025.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $393805.0 in 2023, then skyrocketed by 224.37% to $1.3 million in 2024, then rose by 21.47% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $1.6 million in Q4 2025, $1.3 million in Q4 2024, and $393805.0 in Q4 2023.